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Summary 
Experiments were designed to study the effect of systemically administered IL-5 on local eosin- 
ophil  accumulation induced by the  intradermal  injection of the  chemokine  eotaxin in  the 
guinea pig.  Intravenous interleukin-5  (IL-5) stimulated a rapid and dramatic increase in the 
numbers  of accumulating eosinophils induced by i.d.-injected eotaxin and,  for comparison, 
leukotriene B 4.  The numbers  of locally accumulating eosinophils  correlated directly with  a 
rapid increase in circulating eosinophils: circulating eosinophil numbers were 13-fold higher 1 h 
after intravenous IL-5 (18.3 pmol/kg).  This increase in circulating cells corresponded with a 
reduction in  the  number of displaceable  eosinophils recovered after flushing out  the  femur 
bone marrow cavity. Intradermal IL-5, at the doses tested, did not induce significant eosinophil 
accumulation. We propose that these experiments simulate important early features of the tis- 
sue response to local allergen exposure in a sensitized individual, with eosinophil chemoattrac- 
tant  chemokines having  an  important local role in  eosinophil recruitment from blood mi- 
crovessels, and IL-5 facilitating this process by acting remotely as a hormone to stimulate the 
release into the circulation of a rapidly mobilizable pool of bone marrow eosinophils. This ac- 
tion of IL-5 would be complementary to the other established activities of IL-5 that operate 
over a longer time course. 
I 
L-5 was first described as a factor that induces differenti- 
.ation and prohferation of bone marrow eosinophils (1- 
3).  Subsequently,  IL-5  has  been  shown  to  have  several 
other properties, including the ability to activate or prime 
eosinophils (4-6) and to prolong their survival in vitro (7). 
IL-5 has  also  been implicated in local eosinophil recruit- 
ment  into  tissues  during  allergic  inflammatory reactions, 
such as those induced by helminths  (8).  IL-5 mR.NA ex- 
pression is upregulated in a number of tissues  during eosi- 
nophilic inflammatory reactions, including those in the air- 
ways (9-11), skin (12), bladder (13), intestinal mucosa (13), 
and heart (14).  IL-5 message can be upregulated in eosino- 
phils themselves, e.g., in the asthmatic lung (15).  Further- 
more,  IL-5 protein has  been detected in bronchoalveolar 
lavage (BAL) fluid from allergen-challenged/sensitized mice 
by ELISA (16), and several studies have shown that neutral- 
izing antibodies to IL-5 suppress eosinophil accumulation 
and  hyperreactivity in  the  lungs  of experimental  animals 
during  allergic  inflammation  (17-20).  Consistent  with 
these observations, intratracheal administration of IL-5 has 
been  shown  to  induce  eosinophil  accumulation  in  the 
guinea pig lung in vivo (21)  and to induce chemotaxis of 
eosinophils  in  Boyden chambers  in  vitro  (4,  6,  22,  23). 
Hence,  IL-5  has  been  described as  a  selective eosinophil 
chemotactic factor (4, 23). 
Against this background, we purified eosinophil chemo- 
attractant activity from the BAL fluid of challenged/sensi- 
tized guinea pigs using three sequential HPLC steps and the 
accumulation of mIn-eosinophils in guinea pig skin as the 
in vivo bioassay.  No chemoattractant activity correspond- 
ing to  IL-5 was  detected in  these  experiments.  A  potent 
and selective eosinophil chemoattractant cationic protein of 
,'o8  kD  was  isolated,  however.  This protein induced the 
rapid accumulation  of mIn-eosinophils  in  the  skin  (sub- 
stantial accumulation seen within 30 rain ofintradermal in- 
jection  [24]),  but did not induce significant accumulation 
of ~In-neutrophils. Microsequencing of the chemoattrac- 
tant revealed a novel 73-amino acid C-C chemokine that 
we  termed "eotaxin" (24,  25).  Eotaxin has  been  cloned, 
and increased mRNA expression has been demonstrated in 
the lungs of sensitized guinea pigs after allergen challenge 
in vivo (26). 
These results are apparently at odds with the notion that 
IL-5  is  an  important eosinophfl chemoattractant in  vivo. 
Paradoxically, however, other studies have clearly demon- 
strated that anti-IL-5 antibodies suppress  eosinophil accu- 
mulation in the same model, as discussed above. 
In  this  paper,  we  report results  obtained from experi- 
ments on eosinophil accumulation in the skin, which show 
marked  synergism  between  locally  administered  eotaxin 
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for this paradox. 
Materials  and  Methods 
Animals.  Male Dunkin Hartley guinea pigs (250-300 g) pur- 
chased from Harlan Olac Ltd. (Bicester, UK) were used in all skin 
assay experiments. Female Dunkin Hartley ex-breeder guinea pigs 
(600-800 g) from the same company were used as eosinophil do- 
nors for preparation ofeosinophil peroxidase (EPO) standards. 
Materials.  Human rlL-5 was purchased from tL & D  Systems 
Ltd.  (Oxford,  UK). Leukotriene B 4 (LTB4)  was purchased from 
Cascade Biochem Ltd.  (Reading, UK).  Guinea pig eotaxin (na- 
tive protein) was prepared from the BAL fluid of allergen-chal- 
lenged animals as  described previously (24).  All other  reagents 
and chemicals were purchased from Sigma Chemical Co. (Poole, 
UK). 
Bioassay of Eosinophil Accumulation in Guinea Pig Skin.  Guinea 
pigs were sedated (Hypnorm: fentanyl citrate/fluanisone; Janssen 
Pharmaceutical  Ltd.,  Oxford,  UK),  0.8  ml/kg  intramuscularly 
and,  after  collection of a  heparinized  (10  U/ml)  blood  sample 
(100 p  J) from the ear vein, IL-5 (18.3 pmol/kg) or PBS vehicle 
(500 ~I ofl0 mM PBS, pH 7.4, containing 0.1% low, <0.1 ng/ 
mg, endotoxin BSA) was administered intravenously. After 1 h, a 
second blood sample was obtained and test agents (eotaxin, LTB4, 
or IL-5 in HBSS/0.1% BSA, pH 7.4) were injected intradermally 
into the shaved dorsal skin of the animals in duplicate sites (50 ~1 
per site).  2 h after the intradermal injections, a final blood sample 
was collected and the animals were killed by anesthetic overdose. 
The dorsal skin was removed and individual skin sites (11 mm in 
diameter) were excised and frozen at -80~  Total and differen- 
tial circulating leukocyte numbers were  determined in Kimura- 
stained preparations after red blood cell lysis using Immuno-Lyse 
reagent (Coulter Electronics Ltd., Luton, UK). 
Bone Marrow Eosinophil Release Experiments.  In  separate  ex- 
periments, the kinetics of onset of blood eosinophilia induced by 
intravenous IL-5 was studied. Furthermore, the potential role of 
the bone marrow as a source of these additional cells was investi- 
gated. Blood samples were collected before as well as 5,  15, 30, 
and 60 min after intravenous injection of IL-5 or PBS for total 
and differential leukocyte counts as described above. At the  1-h 
time point,  the  left  femur  was  isolated,  the  femoral  head  and 
condyles were removed, and the displaceable cells were recovered 
by flushing the  marrow  cavity  of the  femur  shaft  with  25  ml 
HBSS containing 30 mM Hepes, 0.1% BSA, and 10 mM EDTA. 
After centrifugation (250 g,  10 min, 20~  the cell pellet was re- 
suspended in 1 ml of the HBSS buffer. Total nucleated cells and 
the  number of eosinophils were  determined in Kimura-stained 
preparations. 
Preparation of Skin Homogenate  for Measurement of EPO Activity. 
Skin samples were extracted for EPO using a modification of the 
method described by Pettipher et al.  (27).  Frozen skin sites were 
chopped during thawing, and after addition of 4 ml PBS contain- 
ing 0.5% hexadecyltrimethylammonium bromide (HTAB), sam- 
ples  were  homogenized  (Ultra-turrax  T25; Janke  and  KunKel 
GmbH and Co., Staufen, Germany, 3 X  15 s), sonicated (Soniprep 
150; MSE Scientific Instruments, Crawley, UK, 10 s), and frozen 
at  -80~  On the  day of EPO  measurement, homogenate was 
thawed and centrifuged twice (2,800 g, 10 min, 20~  and 13,000 
g, 20 rain, 20~  The recovered supematant was then incubated 
at  60~  for 2  h  before a  final centrifugation step  (13,000 g,  10 
rain, 20~  to produce sample supernatant suitable for measure- 
ment of EPO. 
Measurement of EPO in Skin Homogenate.  EPO  was  measured 
using a modification of the method described by Strath et al. (28). 
Processed skin homogenate was placed in duplicate wells (100 Ixl 
per well) in a 96-well plate followed by addition of 100 Ixl sub- 
strate (8.6 mM 0-phenylenediamine dihydrochloride and 2.9 mM 
hydrogen peroxide in 0.1  M  Tris/HC1, pH 8.0). After 30 rain at 
room temperature, the reaction was stopped by the addition of 50 
txl 4 M sulphuric acid and the absorbance read at 492 nm. 
Guinea pig EPO  standard was prepared using eosinophils re- 
covered  from  the  peritoneal cavity of donor animals given re- 
peated  intraperitoneal  injections  of  horse  serum  and  purified 
(>98.5%) over Percoll gradients as described previously (29).  Af- 
ter red blood cell lysis (resuspension in 0.2% NaC1 for 20 s, then 
addition of an equal volume of 1.6% NaC1),  aliquots of eosino- 
phils (106 cells per ml PBS/0.5% HTAB) were frozen at -80~ 
Thawed aliquots were sonicated (10 s), incubated at 60~  for 2 h, 
centrifuged (13,000 g,  20  min, 20~  and the  supernatant was 
used to construct an EPO calibration curve (80-10,000 cells per 
well). The cross-reactivity with guinea pig neutrophil myeloper- 
oxidase  was  <1%  using this  assay.  The  equivalent number of 
eosinophils per skin site was calculated from the standard curve. 
EPO standards and skin homogenates were diluted in PBS/0.5% 
HTAB, pH 7.4. 
Statistical Analysis.  Statistical  analysis  of  circulating  eosino- 
phil numbers within animals and between control and treatment 
groups  was  determined  on  untransformed  data  using repeated 
measures  analysis  of variance  followed  by  the  Tukey-Kramer 
multiple comparisons test. Statistical analysis of skin responses and 
bone marrow eosinophil numbers was carried out on logl0-trans- 
formed data using an unpaired two-tail Student's t test as indi- 
cated in the figure legends. P <0.05 was considered to be statisti- 
cally significant. 
Results 
Effect  of  Intravenous  IL-5  on  the  Local  Accumulation  of 
Eosinophils  Induced  by Intradermal Eotaxin and L TB 4.  Exper- 
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Figure 1.  The effect of intravenous IL-5 on the local accumulation of 
eosinophils in response to intradermal eotaxin and LTB  4. Eosinophil ac- 
cumulation over 2 h induced by intradermal eotaxin and LTB4 (50 p,1 per 
site) 1 h after intravenous administration of IL-5 or vehicle (PBS/0.1% 
BSA). Results represent the number ofeosinophils per skin site +- SEM (n 
=  6). A significant difference between test and control groups is indicated 
by *(P <0.05). 
1170  Eosinophil Accumulation Induced by an IL-5/Eotaxin Interaction In Vivo iments were aimed at investigating the effect ofsystemicaUy 
administered  IL-5  on  local  eosinophil  accumulation  in- 
duced by intradermally  injected  eotaxin and,  for compari- 
son, LTB  4. Preliminary experiments suggested that intrave- 
nous  IL-5  had  a  remarkably  rapid  enhancing  effect  on 
eosinophil accumulation  in the skin.  The study was  there- 
fore designed to  address  specifically the acute effects of in- 
travenous  IL-5.  IL-5  (18.3  pmol/kg)  or  vehicle  was  in- 
jected intravenously into six pairs of guinea pigs.  1 h  later, 
eotaxin and LTB  4 were injected intradermally and  eosino- 
phil accumulation was measured after an additional 2  h. 
Intradermal  injection of either eotaxin  (0.31-1.95  pmol 
per site)  or LTB4  (16-100  pmol  per  site)  induced  a  small 
dose-related  eosinophil  accumulation  in the  control group 
of animals,  which  was  significant  (P <0.05)  at  the highest 
dose  of eotaxin and  the two higher doses of LTB4  (Fig.  1, 
open symbols). In animals  injected intravenously with  IL-5, 
the  eosinophil  accumulation  in  response  to  eotaxin  and 
LTB  4 (Fig.  1,  filled symbols)  was  dramatically  increased  at 
all  the  doses  tested,  except  the  lowest  dose  of  eotaxin, 
when  compared with the control group.  Under these con- 
ditions,  eotaxin was  ~30  times more potent  than  LTB  4 as 
an eosinophil chemoattractant. 
Effect of lntradermally Injected IL-5.  IL-5  or  vehicle  was 
injected  intravenously  into  another  four  pairs  of  guinea 
pigs.  1 h  later,  IL-5  (0.32-2.90  pmol/site)  was injected in- 
tradermally  and  eosinophil  accumulation  was  determined 
after an additional 2  h  as before.  No  significant local eosin- 
ophil accumulation was induced by intradermal  IL-5 in ei- 
ther set of animals  at the  doses  used  (Fig.  2).  The positive 
control  used  in  these  experiments  was  LTB4,  which  gave 
responses similar to those in Fig.  1. 
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Figure 2.  The effect of intravenous  IL-5 on the local accumulation  of 
eosinophils in response to intradetmal  IL-5 and LTB  4. Eosinophil  accu- 
mulation over 2 h induced by intradermal IL-5 and LTB  4 (50 p,l per site) 
1 h after intravenous  administration  of IL-5 or vehicle (PBS/0.1% BSA). 
Results represent the number ofeosinophils per skin site •  SEM (n =  4). 
A significant difference between test and control groups is indicated  by 
*(P <0.05). 
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Circulating  eosinophil  numbers  after intravenous  IL-5  (re- 
sults from the experiments shown in Fig. 1). Circulating eosinophil num- 
ben over 3 h after intravenous  administration oflL-5 or PBS/0.1%  BSA. 
Results  represent  the number  of eosinophils  per milliliter  of blood  + 
SEM (n =  6). A significant difference between circulating levels pre- and 
postintravenous  treatment  within a group  is indicated  by #  (P <0.05), 
and at a given time point between groups by *(P <0.05).  Similar results 
were obtained  in the group of animals used to investigate the eosinophil 
accumulation  induced by i.d. IL-5 (Fig. 2), i.e., intravenous  IL-5 (n =  4) 
induced a significant increase in circulating eosinophils after 1 h (17.3 + 
6.3 ￿  104 cells per ml; P <0.05), but not at 3 h (9.9 --- 0.9 ￿  104 cells per 
ml) when compared  with the preinjection  level (0 h;  1.0 +  0.6  ￿  104 
cells per ml). In the vehicle-injected controls (n =  4), the number of cir- 
culating  eosinophils  did not change  significantly during the 3-h period 
(i.e., 0-h level; 4.5  --- 2.7  X 104 cells per ml, 1-h level; 7.5  +  3.6  ￿  104 
cells per ml, 3-h level; 11.9 --- 2.4 ￿  10  4 cells per ml). 
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Figure  4.  The kinetics of the onset of blood eosinophilia induced  by 
intravenous  IL-5 and the associated changes in the bone marrow pool of 
eosinophils. (a) Circulating eosinophil numbers over 1 h after intravenous 
IL-5 or PBS/0.1%  BSA. Results represent the number of eosinophils per 
ml blood +  SEM (n =  4). A significant difference between circulating 
levels pre- and postintravenous  treatment  within a group is indicated  by 
#  (P <0.05), and at a given time point between groups by *(P <0.05). 
(b) Femur bone marrow eosinophil numbers displaced by flushing 1 h af- 
ter intravenous IL-5 or PBS/0.1%  BSA. Results represent the number of 
bone marrow eosinophils  +  SEM (n =  6). The total number of nucle- 
ated cells recovered from the femurs in the IL-5 and PBS groups was 6.4 
•  0.5  X  107 cells and 7.1  +  0.8  ￿  107 cells, respectively. A significant 
difference is indicated by **(P <0.01). In these experiments, the circulat- 
ing eosinophil  numbers were: pre-IL-5, 8.1  +  4.2  ￿  104 and 1 h post- 
IL-5, 28.8  +  7.2  ￿  104; pre-PBS,  8.4 +  3.3  ￿  104 and 1 h post-PBS,  3 
+  0.4 X 104. 
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Figure  5.  The relationship between cir- 
culating eosinophil numbers and the local 
accumulation of eosinophils induced by eo- 
taxin and LTB  4. Regression analysis of cir- 
culating eosinophils at the time of intrader- 
real injection ofeotaxin (1.95 pmol per site) 
or LTB  4 (100 pmol per site) and the local 
accumulation  of  eosinophils induced by 
these agonists over 2 h (results from the ex- 
periments shown in Fig. 1). Each point rep- 
resents the  determination from a separate 
animal, those receiving intravenous IL-5 (n 
= 6) being indicated by the closed symbols 
and those receiving intravenous vehicle (n 
=  6) by the open symbols. The solid lines 
show linear regression, and the Spearman rank correlation coefficients (r~) are also indicated. A linear regression with a significant r~ was also seen with the 
two lower doses of  each agonist, i.e., eotaxin: 0.78 and 0.31 pmol per site giving rs = 0.902 (P <0.0001) and r  s = 0.769 (P <0.004), respectively; LTB4: 
40 and 16 pmol per site giving r  S  = 0.895 (P <0.0001) and r  5 = 0.706 (P <0.02), respectively. 
The  Effect  of  Intravenous  11.-5  on  Circulating  Eosinophil 
Numbers.  In the experiments described above, blood sam- 
ples were taken before intravenous injections,  as well as  1 
and  3  h  thereafter,  i.e.,  at  the  beginning  and  end  of the 
measurement period of  local cell accumulation. Blood eosin- 
ophil  counts  from the  experiments  using intradermal  eo- 
taxin  (Fig.  1)  are  shown  in  Fig.  3.  Intravenous  IL-5  in- 
duced a remarkably rapid effect on circulating eosinophils, 
as  reported  in  a  preliminary  study  (30).  Intravenous  IL-5 
(18.3 pmol/kg)  induced a  13-fold increase in the numbers 
of circulating eosinophils at 1 h, when compared with pre- 
injection  levels  (Fig.  3).  Variability  between  animals  was 
marked.  Circulating eosinophil numbers also rose in vehi- 
cle-injected  control  animals,  possibly because  of handling 
or anesthesia;  this increase was slow, with numbers signifi- 
cantly above preinjection levels at 3  h.  The difference be- 
tween  circulating  eosinophll  numbers  in  animals  injected 
intravenously with  [L-5  or vehicle was  significant at  1 h, 
but  not  at  3  h.  A  similar  effect  on  circulating  eosinophil 
numbers induced by intravenous  IL-5 was observed in the 
second group of animals shown in  Fig.  2.  (see  Fig.  3  leg- 
end). 
A further set of experiments were designed to investigate 
the time of onset of blood eosinophilia induced by intrave- 
nous IL-5; these results are shown in Fig. 4 a.  The signifi- 
cant increase in blood eosinophils observed 1 h  after intra- 
venous  IL-5 was  associated  with  a  significant  decrease  in 
the number of displaceable  eosinophils recovered from the 
shaft of the femur after a 25-ml flush of the marrow cavity 
(Fig. 4 b). 
Analysis of the  data  on eosinophil  accumulation in  the 
skin revealed a significant direct correlation between eosin- 
ophll accumulation in response to a given dose of eotaxin 
or LTB  4 and the  number of circulating eosinophils at  1 h 
after intravenous injection of IL-5 or vehicle, as shown in 
Fig. 5. This was significant for all three doses of the chemo- 
attractants used (see  Fig. 5 legend). 
Discussion 
This study on the accumulation of eosinophils in guinea 
pig skin demonstrates that IL-5, at the doses tested,  has lit- 
tle  chemoattractant  activity in  this  in vivo system.  A  low 
dose  of IL-5  administered  intravenously,  however,  has  a 
rapid and dramatic enhancing effect on eosinophil accumu- 
lation induced by intradermaUy injected eotaxin. The same 
effect was also observed with  intradermal  LTB4,  which at 
lower potency, also induces eosinophil accumulation in this 
species (29). 
These  observations  can  provide  an  explanation  for the 
results  of previous  studies,  demonstrating  that  acutely ad- 
ministered neutralizing antibodies  to IL-5 suppress eosino- 
phil accumulation in allergen-challenged/sensitized animals 
in vivo. Our results, however, do not support the inference 
that  IL-5  is  an  important  eosinophil  chemoattractant  in 
vivo. It should be noted that previous studies showing a di- 
rect chemoattractant activity of IL-5 required high doses in 
vivo (21)  and high concentrations in vitro  (6).  Higher in- 
tradermal doses oflL-5 were not used in our study to avoid 
the complications imposed by a proportion of the cytokine 
gaining access to the circulation. 
The numbers of eosinophils accumulating in response to 
intradermal  eotaxin correlated with an increase in circulat- 
ing eosinophil numbers induced by intravenous IL-5. The 
blood  eosinophilia  induced  by  intravenous  IL-5  was  re- 
markably rapid in onset. This eosinophilia correlated with a 
significant  decrease  in  the  number  of displaceable  eosino- 
phils recovered from the shaft of the femur, suggesting the 
presence  of a  rapidly  mobilizable  bone  marrow  pool  of 
eosinophils.  Further support for this is provided by the ob- 
servation that the blood eosinophilia seen 1 h after IL-5 ad- 
ministered  intravenously through  the  ear was substantially 
reduced by previous occlusion of the blood supply to the 
hind limbs  (A.  Das,  S.M.  Rankin,  P.D.  Collins,  and T. J. 
Williams,  unpublished  observations).  The  cells  released 
from the bone marrow by IL-5 may be at different stages of 
maturity; there are no available markers to distinguish these 
in the guinea pig.  The cells  appearing in the blood, how- 
ever,  are  clearly able  to  migrate  rapidly  into  tissues.  The 
presence ofa mobilizable pool of bone marrow eosinophils 
has  been  suggested  previously  (31,  32).  In  these  studies, 
however,  the  release  of the  cells  was  demonstrated  1-2  d 
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indicate  that this pool of eosinophils may in fact be avail- 
able within a very short time (<1  h) after appropriate stim- 
ulation.  In addition  to releasing  cells  from the  bone mar- 
row, IL-5 may contribute to local eosinophil accumulation 
by further mechanisms, e.g., eosinophil priming and/or fa- 
cilitating their migration through the microvascular endot- 
helium, as suggested in other studies (4, 6, 33-35). 
Taking all  these observations together, we postulate  the 
following  sequence  of events.  Eotaxin  expression  is  ob- 
served in naive guinea pig tissues  (26)  and may, therefore, 
be involved in a slow recruitment  of eosinophils to main- 
tain the tissue cell numbers under basal conditions.  On ex- 
posure of a tissue to allergen in a sensitized animal,  there is 
an  upregulation  of eotaxin  mRNA  (26)  and  an  early ap- 
pearance of protein  (24). Eotaxin will be unable to induce 
recruitment to any great extent, however, if circulating cell 
numbers are low.  IL-5 is also secreted locally in the tissue, 
but we propose that its initial role is hormonal, i.e.,  it cir- 
culates in the blood and stimulates  the release  of a rapidly 
mobilizable pool of bone marrow eosinophils.  The syner- 
gism between  remotely acting IL-5 and locally acting eo- 
taxin will then induce a rapid recruitment of eosinophils in 
the  allergen-stimulated  tissue.  In the  longer term,  the  ef- 
fect of IL-5 on eosinophiI differentiation  and proliferation 
would manifest itsetfin an increased pool of available eosin- 
ophils  in  the  bone  marrow  and  increased  circulating  cell 
numbers.  Furthermore,  together  with  other  factors,  IL-5 
can  enhance  eosinophil  survival  (22)  and  responsiveness 
(20) once the cells have accumulated in the allergen-stimu- 
lated tissue. 
We believe that these experiments,  showing cooperation 
between  a  chernokine  and  IL-5,  simulate  important  early 
events in the acute allergic reaction, which ensures a rapid 
accumulation  of eosinophils  in tissues  exposed  to allergen 
in the sensitized individual. 
We are indebted  to the WeUcome Trust,  U.K., and the National Asthma Campaign,  U.K., for generously 
supporting  this research.  Dr.  S. Marleau  is a visiting fellow from the Faculty of Pharmacy,  University  of 
Montreal,  Montreal,  Quebec, Canada. 
Address correspondence  to Professor T. J. Williams, Department of Applied Pharmacology,  National Heart 
and Lung Institute, Dovehouse Street, London SW3 6LY, UK. 
Received  for publication 23 February 1995 and in revised  form  14June  1995. 
References 
1. Sanderson,  C.J., D.G. Warren, and M. Strath.  1985. Identifi- 
cation of a lymphokine that stimulates  eosinophil differentia- 
tion in vitro. Its relationship  to interleukin 3, and functional 
properties of eosinophils  produced in cultures. J. Exp. Med. 
162:60-74. 
2.  Clutterbuck, E.J., and C.J.  Sanderson.  1988.  Human eosino- 
phil hematopoiesis studied in vitro by means ofmurine eosin- 
ophil differentiation  factor (IL-5): production of functionally 
active eosinophils  from normal human bone marrow. Blood. 
71:646-651. 
3.  Yamaguchi, Y., T. Suda, J.  Suda,  M. Eguchi, Y. Miura, N. 
Harada,  A. Tominaga, and K. Takatsu.  1988. Purified inter- 
leukin  5  supports  the terminal  differentiation  and prolifera- 
tion ofmurine eosinophilic precursors.J.  Exp. Med. 167:43- 
56. 
4.  Sehmi,  R.,  A.J.  Wardlaw,  O.  Cromwell,  K.  Kurihara,  P. 
Waltmann, and A.B. Kay. 1992. Interleukin-5 selectively en- 
hances the chemotactic response ofeosinophils obtained from 
normal but not eosinophilic  subjects.  Blood. 79:2952-2959. 
5. Warringa, R.A.J., H.J.J.  Mengelers,  P.H.M.  Kuijper, J.A.M. 
Raaijmakers,  P.L.B.  Bruijnzeel,  and L.  Koenderman.  1992. 
In vivo priming of platelet-activating  factor-induced eosino- 
phil chemotaxis in allergic  asthmatic  individuals.  Blood. 79: 
1836-1841. 
6.  Coeftier, E., D. Joseph, and B.B. Vargaftig.  1991. Activation 
of guinea pig eosinophils  by human recombinant IL-5. Selec- 
tive priming to platelet-activating factor-acether and interfer- 
ence of its antagonists.J. Immunol. 147:2595-2602. 
7.  Tai, P.C., L. Sun, and C.J.F. Spry. 1991. Effects oflL-5, gran- 
ulocyte/macrophage  colony-stimtflating  factor  (GM-CSF) 
and IL-3 on the survival of human blood eosinophils  in vitro. 
Clin. Exp. Immunol. 85:312-316. 
8.  Coffman, R.L., B.W.P. Seymour, S. Hudak, J. Jackson, and 
D.  Rennick.  1989.  Antibody to interleukin-5  inhibits  hel- 
minth-induced  eosinophilia  in  mice.  Science (Wash. DC). 
245:308-310. 
9.  Sedgwick, J.B.,  W.J.  Calhoun,  G.J.  Gleich,  H.  Kita,  J.S. 
Abrams,  L.B.  Schwartz,  B.  Volovitz, M. Ben-Yaakov,  and 
W.W. Busse. 1991. Immediate and late airway response of al- 
lergic  rhinitis  patients  to  segmental  antigen  challenge.  Am. 
1173  Collins et al.  Brief Definitive Report Rev. Respir.  Dis.  144:1274-1281. 
10. Hamid, Q., M. Azzawi, S. Ying, R. Moqbel, A.J. Wardlaw, 
C.J.  Corrigan, B. Bradley, S.R. Durham, J.V.  Collins, P.K. 
Jeffery, D.J. Quint, and A.B. Kay. 1991.  Interleukin-5 in the 
pathogenesis of asthma. J.  Clin. Invest.  87:1541-1546. 
11. Krishnaswamy, G., M.C.  Liu, S.-N.  Su, M.  Kumai, H.-Q. 
Xiao, D.G.  Marsh, and S.-K. Huang.  1993.  Analysis of cy- 
tokine transcripts in the bronchoalveolar lavage cells of pa- 
tients with asthma. Am..].  Respir.  Cell Mol.  Biol.  9:279-286. 
12. Kay, A.B., S. Ying, V. Vamey, M.  Gaga, S.R. Durham, R. 
Moqbel,  A.J.  Wardlaw,  and  Q.  Hamid.  1991.  Messenger 
RNA expression of the cytokine gene cluster, interleukin 3 
(IL-3),  IL-4,  IL-5,  and  granulocyte/macrophage  colony- 
stimulating factor,  in allergen-induced late-phase cutaneous 
reactions in atopic subjects.J. Exp.  Med.  173:775-778. 
13. Dubucquoi,  S.,  P.  Desreumaux,  A. Janin,  O.  Klein,  M. 
Goldman, J.  Tavernier, A. Capron, and M.  Capron.  1994. 
lnterleukin 5 synthesis by eosinophils: association with gran- 
ules and immunoglobulin-dependent secretion. J.  Exp.  Med. 
179:703-708. 
14. Desreumaux, P., A. Janin, S. Dubucquoi,  M.-C. Copin, G. 
Torpier, A. Capron, M. Capron, and L. Prin. 1993.  Synthesis 
of interleukin-5  by  activated  eosinophils  in  patients  with 
eosinophilic heart diseases. Blood.  82:1553-1560. 
15. Broide, D.H., M.M. Paine, and G.S. Firestein. 1992. Eosino- 
phits express interleukin 5 and granulocyte macrophage-col- 
ony-simulating factor mRNA at sites of allergic inflammation 
in asthmatics.J. Clin. Invest.  90:1414-1424. 
16. Yamaguchi, S., H. Nagai, H. Tanaka, M. Tsujimoto, and N. 
Tsuruoka.  1994.  Time course study for antigen-induced air- 
way hyperreactivity and the effect of soluble IL-5 receptor. 
Life Sciences. 54:471-475. 
17. Chand, N., J.E. Harrison, S. Rooney, J. Pillar, R. Jakubicki, 
K. Nolan,  W. Diamantis, and R.D.  Sofia.  1992.  Anti-IL-5 
monoclonal  antibody  inhibits  allergic late  phase  bronchial 
eosinophilia in guinea pigs: a  therapeutic approach. Eur. J. 
PharmacoI. 211:121-123. 
18. Van Oosterhout, A.J.M., R.S. Ladenius, H.F.J. Savelkoul, I. 
Van Ark, K.C. Delsman, and F.P. Nijkamp.  1993.  Effect of 
anti-IL-5 and IL-5 on airway hyperreactivity and eosinophils 
in guinea pigs. Am. Rev. Respir.  Dis.  147:548-552. 
19. Mauser, P.J., A. Pitman, A. Witt, X. Fernandez, J.  Zurcher, 
T. Kung, H. Jones, A.S. Watnick, R.W. Egan, W. Kreutner, 
and  K.G.  Adams.  1993.  Inhibitory effect  of the  TRFK-5 
anti-IL-5 antibody in a guinea pig model of asthma. Am. Rev. 
Respir.  Dis.  148:1623-1627. 
20.  Coeffier, E., D. Joseph, and B.B. Vargaftig. 1994. Role ofln- 
terleukin-5 in enhanced migration of eosinophils from air- 
ways of immunized guinea-pigs. Br. J.  Pharmacol.  113:749- 
756. 
21.  Iwama, T., H. Nagai, H. Suda, N. Tsuruoka, and A. Koda. 
1992.  Effect ofmurine recombinant interteukin-5 on the cell 
population in guinea-pig airways. Br. J.  Pharmacol.  105:19- 
22. 
22. Yamaguchi, Y., Y. Hayashi, Y. Sugama, Y. Miura, T. Kasa- 
hara,  S.  Kitamura,  M.  Torisu,  S.  Mira,  A.  Tominaga,  K. 
Takatsu, and T. Suda. 1988. Highly purified murine interleu- 
kin 5  (IL-5) stimulates eosinophil function and prolongs in 
vitro  survival.  IL-5  as  an  eosinophil chemotactic  factor. J. 
Exp. Med.  167:1737-1742. 
23.  Wang, J.M., A. Rambaldi, A. Biondi, Z.G. Chen, C.J. Sand- 
erson, and A. Mantovani. 1989.  Recombinant human inter- 
leukin 5 is a selective eosinophil chemoattractant. Eur. J. Im- 
munol.  19:701-705. 
24. Jose, P.J.,  D.A. Griflqths-Johnson, P.D. Collins, D.T. Walsh, 
R.  Moqbel,  N.F.  Totty,  O.  Truong, J.J.  Hsuan,  and  T.J. 
Williams. 1994. Eotaxin: a potent eosinophil chemoattractant 
cytokine detected in a guinea-pig model of allergic airways 
inflammation.J. Exp. Med.  179:881-887. 
25.  Griffiths-Johnson, D.A., P.D.  Collins, A.G. Rossi, P.J. Jose, 
and T.J. Williams. 1993.  The chemokine, Eotaxin, activates 
guinea-pig eosinophils in vitro, and causes their accumulation 
into the lung in vivo. Biochem.  Biophys.  Res.  Commun.  197: 
1167-1172. 
26. Jose, P.J., I.M. Adcock, D.A. Griffiths-Johnson, N. Berkman, 
T.N.C.  Wells, T.J.  Williams, and  C.A.  Power.  1994.  Eo- 
toxin: cloning of an eosinophil chemoattractant cytokine and 
increased mRNA expression in allergen-challenged guinea- 
pig lungs. Biochem.  Biophys.  Res.  Commun.  205:788-794. 
27. Pettipher, E.R., E.D.  Salter, and H.J.  Showell.  1994.  Effect 
of in vivo desensitization to leukotriene B4 on eosinophil in- 
filtration in response to C5a in guinea-pig skin. Br. J. Pharma- 
col. 113:117-120. 
28. Strath, M., D.J. Warren, and C.J. Sanderson. 1985. Detection 
of eosinophils using an eosinophil peroxidase assay. Its use as 
an  assay  for  eosinophil  differentiation factors. J.  lmmunol. 
Methods.  83:209-215. 
29.  Faccioli, L.H.,  S.  Nourshargh,  R.  Moqbel,  F.M.  Williams, 
R. Sehmi, A.B. Kay, and T.J. Williams. 1991.  The accumu- 
lation of lltln-eosinophils induced by inflammatory media- 
tors in vivo. Immunology.  73:222-227. 
30. Sanjar, S., P. McCabe, and L. Reynolds. 1992.  Recombinant 
human IL-5 (rh-IL5) induces a rapid and selective blood eosi- 
nophilia in the guinea-pig. Am. Rev. Respir.  Dis. (Proc. Suppl.) 
143:A14P. (Abstr.) 
31.  Hudson,  G.  1963.  Changes  in the bone marrow reserve of 
eosinophils following re-exposure to foreign protein. Br. J. 
Haematol.  9:446-455. 
32. Hudson, G. 1964.  The marrow reserve of eosinophils. Effect 
of cortical hormones on the foreign protein response. Br. J. 
Haematol.  10:122-130. 
33. Schweizer, R.C.,  B.A.C. Welmers, J.A.M.  Raaijmakers, P. 
Zanen,  J.-W.J.  Lammers,  and  L.  Koenderman.  1994. 
RANTES-  and  interleukin-8-induced responses  in  normal 
human  eosinophils:  effects  of priming  with  interleukin-5. 
Blood.  83:3697-3704. 
34. Ebisawa, M., M.C. Liu, T. Yamada, M. Kato, L.M. Lichten- 
stein, B.S.  Bochner,  and R.P.  Schleimer.  1994.  Eosinophil 
transendothelial migration induced by cytokines II. Potentia- 
tion of eosinophil transendothelial migration by eosinophil- 
active cytokines.J, lmmunol.  152:4590-4596. 
1174  Eosinophil Accumulation Induced by an IL-5/Eotaxin Interaction In Vivo 